Tolerance Bio emerges from stealth with $17.2M to advance therapies developed from the thymus

Katherine Lewin

News Reporter

Tolerance Bio has launched with an oversubscribed $17.2 million seed round and a goal to develop therapies for immune-mediated diseases, from cancer to transplant rejection …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Tolerance Bio emerges from stealth with $17.2M to advance therapies developed from the thymus

Katherine Lewin

News Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Tol­er­ance Bio emerges from stealth with $17.2M to ad­vance ther­a­pies de­vel­oped from the thy­mus

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Tolerance Bio emerges from stealth with $17.2M to advance therapies developed from the thymus